araris: a landmark exit for redalpine and swiss biotech unicorn

We are delighted to announce a major milestone from our portfolio: Araris Biotech AG (RAC IV) has been acquired by Taiho Pharmaceutical in a landmark deal exceeding $1 billion. This marks a major success for Swiss biotech innovation and a significant step forward in the battle to cure cancer. Araris Biotech has been pioneering next-generation antibody-drug conjugate (ADC) technology, aiming to revolutionize targeted cancer therapies. Their proprietary AraLinQ™ platform enables site-specific, highly stable, and efficient ADCs designed to enhance both safety and efficacy. The acquisition further validates the strength of Araris' innovation and its potential to transform cancer treatment.

At redalpine, we believe in empowering founders from the earliest stages. We were the first-check investor in Araris back in 2019, recognizing the transformative potential of their ADC technology. Our team, led by Founding Partner Michael Sidler, has worked closely with the Araris founders ever since, supporting them throughout their journey to becoming a global biotech leader.

This acquisition highlights the power of deep tech, biotech, and life sciences innovation in Europe. It also reinforces redalpine’s commitment to backing bold ideas at the connection of software and science - where breakthroughs happen. We are incredibly proud to see a homegrown Swiss biotech company reach unicorn status and make a meaningful impact in healthcare.